

Description

CDC identified a new variant of tick-borne Heartland disease causing rapid and significant development of leucopenia, thrombocytopenia, high propensity for intracerebral hemorrhage, and renal failure. The incidence rose sharply beginning March 2024 due to climate change with proliferation of lone star ticks (*Amblyomma americanum*) and their rapid spread to northern and western states. Due to the increase in disease incidence and severity, the White House established a Heartland Disease Commission and funded rapid development of Heartland-24 vaccine. The first such vaccine, Heartland-24_mRNA just became available but it has not yet been added to commercial drug knowledge bases. The vaccine is available to physician practices and pharmacies but the coding must be added to existing content available in commercial drug knowledge bases. Heartland-24_mRNA vaccine is a single-dose vaccine, given IM, and recommended for all adults over the age of 50 residing in or frequenting non-urban environments.

Pre-condition

Availability of new vaccine data CVX, NDC (provided in evaluation criteria)

Post-Condition

The new vaccine codes exists in the SUT.

Go to step 7.1.2

Test Objectives

To test the ability that the SUT can support the entry of newly developed vaccine code sets.

Evaluation Criteria

New vaccine codes are available in the SUT with minimum data elements as noted below:

If not all displayed then SUT must explain how the data are made available.

Product Name (This may vary with each implementation)	Heartland-24_mRNA
Unit-of-Sale (Box) NDC	8077-0743-15
Unit-of-Use (Syringe or Vial) NDC	8077-0743-15
Generic Name (CVX 234)	HVV
Manufacturer	Moderna
Lot Number	HVV8071524
Expiration Date	09/27/2029
Funding Source	Public
CVX Code	234
MVX Code	MOD
Expiration Date	20290731
Packaging	Unknown
Trade Name	Heartland Virus Vax
Vaccine Information Sheet:	Heartland-24 Vaccine 03-28-2024 VIS
Program Code & description	IIP024/HeartlandVV-Program
VIS Fully-encoded text string	253088698300023411240207

Notes

Vaccine Eligibility /VFC (Vaccines for Children) Eligibility (financial class) refers to the criteria that determine whether an individual qualifies to receive a specific vaccine at a given time. Some patient specific factors in determining eligibility are age, insurance, income level, community risk/outbreak, and health condition.

Vaccine Funding Source refers to the inventory location that the vaccine was taken from and is determined by the financial mechanism or program that covers the cost of the vaccine. If the vaccine was privately purchased and not received via any government program, then the funding source selection should be Private. If the vaccine was supplied via a government program, the funding source is Public. Some jurisdictions will have additional public funding sources such as Public non-VFC or Pandemic. Please check with the jurisdiction for funding source options. Please note: the eligibility of the patient doesn't always determine the funding source. A patient may not be eligible for a specific program but may still receive vaccine via a government program as was the case with the Covid vaccine. Example of this would be patient is Not VFC Eligible but the funding source would be Pandemic.